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Abstract
It is well established that interleukin-6 (IL-6) is an essential growth
factor for multiple myeloma (MM) and patients with increased IL-6
levels have a poor prognosis. In healthy subjects, the presence of the
C allele at a polymorphic site (-174 G/C) of the IL-6 gene is related to
low IL-6 levels. In view of the potential association of this particular
polymorphism with IL-6 concentration, and the relevance of IL-6 in
MM pathogenesis, the objective of the present study was to investi-
gate the prevalence of IL-6 (-174 G/C) promoter polymorphism and
its association with development of MM in Brazilian individuals. We
investigated the prevalence of these alleles in 52 patients and 60
healthy subjects (matched by age, sex, and race) of a Brazilian
population. Thirty patients were male (42.4%), 24 (46.2%) were white
and the median age at diagnosis was 58.5 years (range: 28 to 84 years).
To determine the IL-6 (-174 G/C) polymorphism, molecular analysis
was performed by polymerase chain reaction followed by endonu-
clease restriction digestion. The genotype distributions observed in
the group of patients were 4% CC, 42% GC and 54% GG. The C allele
frequency was 0.25. These results were similar to the control group,
suggesting no impact of this polymorphism on the susceptibility to
MM.
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Interleukin-6 (IL-6) is a pro-inflamma-
tory cytokine produced by both myeloma
cells (autocrine mechanism) and bone mar-
row myeloid and monocytic cells (paracrine
mechanism), and is considered to be one of
the most important cytokines for plasma cell
proliferation and survival (1). Evidence that
IL-6 is involved in the pathogenesis of mul-
tiple myeloma (MM) was based on experi-
mental and clinical findings: a) IL-6 induces
in vitro growth of myeloma cells freshly
isolated from patients, b) myeloma cells spon-
taneously produced IL-6 and expressed its
receptor, c) anti-IL-6 antibodies inhibited
the growth of MM cells or cell lines in vitro,
and d) treatment of MM patients with mono-
clonal antibodies to IL-6 had some antitumor
effect (2). Thus, IL-6 is considered to be an
essential growth factor for MM and increased
serum IL-6 levels have been associated with
a poor prognosis (1,3).
Regulation of cytokine levels is under
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genetic control through genetic polymor-
phisms in their coding and promoter se-
quences. It seems that the single-nucleotide
polymorphism in the promoter region of the
IL-6 gene at position -174 may regulate the
plasma concentrations of IL-6 in vivo (4-6).
The presence of lysine (allele C) at the gua-
nine site (allele G) is associated with low
levels of plasma IL-6 in healthy subjects.
The CC genotype is considered to be a low
producer and GG a high producer of IL-6
(4,7,8). However, Endler et al. (6) did not
find this association and Brull et al. (9) found
the opposite, i.e., patients with the CC allele
had higher plasma IL-6 levels. Furthermore,
other haplotypes cooperate with the tran-
scriptional regulation of IL-6 influencing its
production (10).
Considering the relevant role of IL-6 in
MM biology and the influence of genetic
polymorphisms on IL-6 production, our ob-
jective was to determine the impact of IL-6
polymorphism on the susceptibility to MM.
Between November 2002 and November
2003, patients with MM or solitary plasma-
cytoma from the MM Outpatient Service of
the Discipline of Hematology and Hemo-
therapy, Universidade Federal de São Paulo
(UNIFESP/EPM), São Paulo, SP, Brazil,
were invited to participate independently of
the time when the diagnosis was made.
The patients were diagnosed according
to the criteria of Durie and Salmon (11) and
most of the data were analyzed prospec-
tively. Plasmacytoma patients were treated
with radiotherapy and MM patients were
initially treated with standard chemotherapy
protocols, namely melphalan and prednisone
or vincristine, doxorubicin and dexametha-
sone.
Healthy individuals matched for age, gen-
der and ethnic characteristics were used as
controls. The study was approved by the
Ethics Committee of Universidade Federal
de São Paulo and all subjects gave written
informed consent to participate.
Genomic DNA was extracted from
EDTA-treated whole blood by standard pro-
teinase K digestion and the phenol/chloro-
form method (12). A 300-bp fragment con-
taining the -174 site according to the se-
quence of the IL-6 promoter region was
amplified by PCR using the following prim-
ers: sense 5'-TTGTCAAGACATGCCAAA
GTG-3' and anti-sense 5'-TCAGACATC
TCCAGTCCTATA-3' (7). Digestion with
the NlaIII restriction enzyme yielded three
fragments when allele C was present (54,
111, and 135 bp) and two fragments were
obtained when allele G was present (54 and
246 bp). Genotype distribution and allelic
frequency and their association with other
variables were analyzed using the chi-square
and Fisher test, respectively.
We studied 52 patients, 30 (42.4%) males.
Twenty-four (46.2%) were white and 28
(53.8%) were African-Brazilians. The me-
dian age at diagnosis was 58.5 years (range:
28 to 84 years). The control group consisted
of 36 (60%) male and 24 (40%) female
healthy individuals; 33 (55%) of them were
Table 1. Distribution of interleukin-6 (IL-6) (-174 G/C) genotypes in the multiple
myeloma and control groups studied.
IL-6 (-174 G/C) Genotype Allele
GG GC CC Total G C Total
Patients
Present study
N 28 22 2 52 78 26 104
Frequency 54% 42% 4% 75% 25%
Mazur et al. (13)
N 11 31 12 54 53 55 108
Frequency 20% 58% 22% 49% 51%
Zheng et al. (7)
N 22 36 15 73 80 66 146
Frequency 30% 49% 21% 55% 45%
Control
Present study
N 35 23 2 60 93 27 120
Frequency 58% 38% 3% 77% 23%
Mazur et al. (13)
N 16 28 6 50 60 40 100
Frequency 32% 56% 12% 60% 40%
Zheng et al. (7)
N 33 69 26 128 135 121 256
Frequency 26% 54% 20% 53% 47%
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African-Brazilians, and median age was 59.3
years (range: 31 to 85 years). The Pearson
chi-square test showed that the two popula-
tions were statistically similar regarding gen-
der and race and the Fisher test demonstrate
age equivalence.
Six patients had solitary plasmacytoma
at diagnosis and only one progressed to MM.
Clinical stage at MM diagnosis was IIA for 3
(5.7%), IIIB for 14 (27%), and IIIA for 28
(53.8%) (data for 1 patient were incom-
plete). Of the 42 cases analyzed, 15 (35.7%)
had the IgG kappa isotype, 6 (14.3%) were
IgG lambda, 5 (11.9%) IgA kappa, and 4
(9.6%) IgA lambda. Twelve (28.5%) pa-
tients presented light chain disease (8 kappa
and 4 lambda).
Genomic analysis did not reveal a differ-
ence between MM patients and controls in
allelic frequency at the -174 position of the
IL-6 gene promoter. The C allele frequency
was 0.25 in the MM group and 0.23 in the
control group (P > 0.05). Although, geno-
type frequency did not differ significantly
between our groups, Table 1 shows the re-
sults obtained in the present study compared
to those reported by other investigators. Our
results are similar to the results reported by
Zheng et al. (7) and Mazur et al. (13). The G
allele frequency was higher in the Brazilian
population (75% among patients and 77%
among controls) than in the European popu-
lation (7,13). This observation could be ex-
plained by the different ethnic background
of the Brazilian population.
Despite the small number of patients en-
rolled, the similarity of the allelic frequency
of the IL-6 polymorphism observed in Bra-
zilian patients and controls suggests that the
polymorphism of this allele has no impact
on the susceptibility to MM.
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